Published in final edited form as:

Anesthesiology. 2016 December ; 125(6): 1085–1087. doi:10.1097/ALN.0000000000001399.

CYP2B6*6 or not CYP2B6*6 – that remains a question for precision medicine and ketamine!

Scott D. Cook-Sather, MD[^], Peter C. Adamson, MD^{*}, Jin Li, PhD[†], and Hakon Hakonarson, MD, PhD[†]

[^]Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

^{*}Department of Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

[†]Department of Pediatrics and the Center for Applied Genomics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

While certainly not the dire existential question posed by Hamlet, could detailed knowledge of variants at *CYP2B6* and other genetic loci bring precision medicine to the clinical dosing of ketamine? We believe that it will, but one nuanced by indication, route of administration, and other factors.

In this issue of Anesthesiology, Rao and colleagues present their work on the pharmacogenetics of ketamine in an attempt to better understand the etiologies of drug response variability, beginning with metabolism and pharmacokinetic differences.¹ Cytochrome P450, family 2, subfamily B, member 6 (*CYP2B6*) is a high-affinity protein thought to predominate ketamine catabolism. The gene coding for *CYP2B6* (*CYP2B6*) is highly polymorphic, with the common *CYP2B6**6 (516G>T, 785A>G) variant, found largely in those of African descent, correlating with diminished hepatic *CYP2B6* expression. Functionally, the associated gene product *CYP2B6*.6 and liver microsomes from *CYP2B6**6 carriers both show reduced ketamine metabolism *in vitro*.² Moreover, in chronic pain patients treated with 100–500 mg/24 h subcutaneous ketamine infusions, the *CYP2B6**6 allele confers reduced steady-state ketamine clearance with gene-dose effect.³

From this foundation, Rao *et al* sought to prove that compared to wild-type *CYP2B6**1/*1 subjects, healthy volunteers heterozygous or homozygous for the *6 minor allele would have reduced ketamine catabolism following low-dose (0.4 mg/kg) oral administration of racemic drug. They chose a gold standard primary outcome of ketamine N-demethylation as determined by plasma norketamine/ketamine area under the concentration-time curve (AUC)

Corresponding author: Scott D. Cook-Sather, MD, Department of Anesthesiology and Critical Care Medicine, Rm 9350, The Children's Hospital of Philadelphia, 34th Street and Civic Center Blvd, Philadelphia, PA 19104-4399 Tel: 215-590-1447; Fax: 215-590-1415; sather@email.chop.edu.

The authors are not supported by nor maintain any financial interest in any commercial activity that may be associated with the topic of this article.

ratio and then carefully planned validation by complementary methods. With the potential for stereoselective effects seen for other chiral medications, they also queried ketamine enantiomer metabolism and disposition with enantioselective mass spectrometry. Surprisingly, they found no difference in ketamine (*R*-, *S*-, or racemic) metabolism as a function of *CYP2B6**6 genotype.

How does one reconcile the disparity between these findings and those of the *in vitro*² and earlier clinical pharmacokinetic studies?³ The authors offer several plausible explanations invoking dose, route of drug administration, and population characteristics. Apart from ethnic variation, we do not believe methodologic or analytical differences to be contributory. Clearance estimates using single time point specimens obtained at steady-state yield equally reliable results to multiple time point measurements made following the first dose of drug. Differences in ketamine disposition resulting from low *versus* high dose also seems unlikely, as we are not aware of any evidence to suggest dose dependent pharmacokinetics that would be observed with a readily saturable elimination pathway.

We suspect that the disparity may at least in part relate to route of administration whereby non-*CYP2B6* dependent intestinal metabolic pathways predominate after oral dosing and mask the impact of hepatic *CYP2B6* variants. Supportive observations include striking differences in norketamine:ketamine metabolic ratios following oral drug administration, yielding ratios of 4.7–7.5,¹ in contrast to 0.4–1.1 ratios following parenteral administration.³ In addition, high circulating concentrations of hydroxynorketamine observed after oral administration is consistent with (but not proof of) significant *CYP3A4* metabolism. Could more extensive metabolism of oral ketamine be driven by intestinal and/or hepatic *CYP3A4*? Though *CYP2B6* exhibits greater ketamine N-demethylation activity per pmol *CYP450* protein, *CYP3A4* is 30 fold more abundant in hepatic microsomes such that, at ketamine concentrations corresponding to analgesic plasma levels, *CYP3A4* contribution to ketamine catabolism per microsome mass is double that of *CYP2B6*.⁴ *CYP3A4* is also abundant in intestinal tissue, and by sequential action in the gut, then mass effect in the liver, it could easily dominate ketamine N-demethylation overall. Several clinical studies support this theory: *CYP3A4* inhibitors clarithromycin⁵ and grapefruit juice⁶ increase S-ketamine plasma concentrations and decrease metabolic ratios, while St. John's Wort, a potent *CYP3A4* inducer, does the opposite.⁷ Though a conflicting study suggested a stronger influence of *CYP2B6* as inhibited by ticlopidine, and a lesser role for *CYP3A4* as inhibited by itraconazole,⁸ we believe that the cumulative evidence points to a route-dependent effect favoring one of the competing catabolic pathways.

What might be done to resolve this? Difference resulting from first pass metabolism is a testable hypothesis: in subjects stratified by genotype, evaluate metabolite/parent plasma concentrations following both enteral and parenteral drug administration. Intravenous administration bypasses intestinal metabolism and hepatic first pass effects and would potentially allow *CYP2B6* variant influences to manifest. The conservative 0.4 mg/kg oral ketamine dose studied was principally chosen for safety reasons, however, larger intravenous doses (0.5–1 mg/kg) are safely used in clinical practice and could be studied with appropriate precautions. Might there be additional important variants to examine? Does the less common *CYP2B6**4 (785A>G) allele increase ketamine metabolism as it did for

methadone?⁹ More well-defined clinical phenotypes should be evaluated for associations with serum ketamine levels and genotype. Validated tools for assessment of experimental pain, sedation, and cognitive and motor impairment should be used. With regard to the self-assessment questions, it is possible that ketamine effects may have gone underreported in the current study. If one is mildly impaired, can one reliably recognize and report it?

Pharmacogenetics/genomics is moving from discovery to validation to early preemptive clinical diagnostics.^{10,11} Efforts through the Pharmacogenomics Knowledgebase (PharmGKB), a partner of the NIH Pharmacogenomics Research Network (PGRN), and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have published guidelines on multiple actionable variants, many of which apply to clinical anesthesiology and pain management.^{12–18} Further, the U.S. Food and Drug Administration has issued a list of pharmacogenomic biomarkers used in labelling 165 medications of which 31 relate to our discipline.¹⁹ Although *CYP2C9*, *CYP2C19*, and *CYP2D6* have prominent, documented roles in drug response variability, increased attention has been directed toward *CYP2B6* which may contribute to as much as 10% of total hepatic CYP content and is associated with 20–250-fold inter-individual variation in protein expression.²⁰ *CYP2B6* has been classified by PharmGKB as an important pharmacogene,²¹ and is included among the 82 pharmacogenes captured and studied in the PGRNseq data from the eMERGE Network.²²

Ketamine has many clinical applications and though its pharmacokinetics and pharmacodynamics are better understood,²³ pharmacogenetic dosing remains in early validation stages. Drugs with strong single-locus genetic effects such as codeine with common *CYP2D6* variants resulting in poor, rapid, or ultra-rapid metabolism have well-validated, unequivocal pharmacogenetic dosing guidelines, offering proof of concept for precision medicine relevant worldwide.^{14,15,24,25} Methadone is in mid-stage validation, with *CYP2B6* variant metabolism effects that must next be tested for utility in larger clinical trials.⁹ Could there be actionable *CYP2B6* variants for ketamine? Although the answer would appear to be no for *CYP2B6*6* and low dose oral ketamine, this does not preclude *CYP2B6*6* or other variants at this locus affecting intravenous or even higher oral dose pharmacokinetics. We believe that ketamine will eventually have pharmacogenetic dosing guidelines, perhaps specific to administration route, that include actionable *CYP2B6* and *CYP3A4* variants. Finally, beyond these candidate genes, novel common variants identified by genome-wide association studies²⁶ and rare variants found through whole genome sequencing will likely add to the test array that brings precision medicine to clinical ketamine use.

We applaud the investigators conducting this study and also ANESTHESIOLOGY'S commitment to publish informative, negative results that help establish application boundaries. We maintain our continuing awe of the complexity and elegance of the processes studied. With substrate-specific gene effects, variability associated with drug administration route, polygenic traits, gene-gene and gene-environment interactions, post-transcriptional changes, and other variables that may alter phenotype and medical care requirements, clinicians can expect complicated, arduous journeys in the development of specific pharmacogenomic guidelines. Precision medicine is part of our future, however, and the detailed information required to advance it is rapidly growing.

Acknowledgments

The authors would like to thank Francis X. McGowan, M.D. and Alan J. Schwartz, M.D. for their expertise in revising the manuscript.

References

1. Rao LK, Flaker AM, Friedel CC, Kharasch ED. Role of cytochrome P450 polymorphisms in ketamine metabolism and clearance. *Anesthesiology*. 2016; XX:YY–ZZ.
2. Li Y, Collier JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA. The *CYP2B6**6 allele significantly alters n-demethylation of ketamine enantiomers *in vitro*. *Drug Metab Dispos*. 2013; 41:1264–72. [PubMed: 23550066]
3. Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Collier JK, Hutchinson MR, Currow DC, Somogyi AA. *CYP2B6**6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse events. *Br J Clin Pharmacol*. 2015; 80:276–84. [PubMed: 25702819]
4. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to n-demethylation of ketamine in human liver microsomes. *Drug Metab Dispos*. 2002; 30:853–8. [PubMed: 12065445]
5. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. *Eur J Pain*. 2010; 14:625–9. [PubMed: 19897389]
6. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. S-ketamine concentrations are greatly increased by grapefruit juice. *Eur J Clin Pharmacol*. 2012; 68:979–86. [PubMed: 22286159]
7. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. St. John's wort greatly decreases the plasma concentrations of oral S-ketamine. *Fund Clin Pharmacol*. 2012; 26:743–50.
8. Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. *Clin Pharmacol Ther*. 2011; 90:296–302. [PubMed: 21716267]
9. Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: *CYP2B6* polymorphisms determine plasma concentrations, clearance, and metabolism. *Anesthesiology*. 2015; 123:1142–53. [PubMed: 26389554]
10. Relling MV, Evans WE. Pharmacogenomics in the clinic. *Nature*. 2015; 526:343–50. [PubMed: 26469045]
11. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Ann Rev Pharmacol Toxicol*. 2015; 55:89–106. [PubMed: 25292429]
12. Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE. PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics. *Pharmacogenet Genomics*. 2015; 25:622–30. [PubMed: 26398623]
13. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther*. 2014; 95:376–82. [PubMed: 24458010]
14. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (*CYP2D6*) genotype. *Clin Pharmacol Ther*. 2012; 91:321–6. [PubMed: 22205192]
15. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for *CYP2D6* and *CYP2C19* genotypes and dosing of tricyclic antidepressants. *Clin Pharmacol Ther*. 2013; 93:402–8. [PubMed: 23486447]

16. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium guidelines for *CYP2C9* and *VKORC1* genotypes and warfarin dosing. *Clin Pharmacol Ther.* 2011; 90:625–9. [PubMed: 21900891]
17. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer SE, Lee MTM, Klein TE, Callaghan JT. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for *CYP2C9* and *HLA-B* genotype and phenytoin dosing. *Clin Pharmacol Ther.* 2014; 96:542–8. [PubMed: 25099164]
18. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot J-S, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (*CYP2C19*) genotype and clopidogrel therapy. *Clin Pharmacol Ther.* 2011; 90:328–32. [PubMed: 21716271]
19. <http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm> accessed 08/04/2016
20. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. *Curr Drug Metab.* 2008; 9:598–610. [PubMed: 18781911]
21. Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for *CYP2B6*. *Pharmacogenet Genomics.* 2010; 20:520–3. [PubMed: 20648701]
22. Bush WS, Crosslin DR, Owusu-Obeng A, Wallace J, Almoguera B, Basford MA, Bielinski SJ, Carrell DS, Connolly JJ, Crawford D, Doheny KF, Gallego CJ, Gordon AS, Keating B, Kirby J, Kitchner T, Manzi S, Mejia AR, Pan V, Perry CL, Peterson JF, Prows CA, Raltson J, Scott SA, Scrol A, Smith M, Stallings SC, Veldhuizen T, Wolf W, Volpi S, Wiley K, Li R, Manolio T, Bottinger E, Brilliant MH, Carey D, Chisholm RL, Chute CG, Haines JL, Hakonarson H, Harley JB, Holm IA, Kullo IJ, Jarvik GP, Larson EB, McCarty CA, Williams MS, Denny JC, Rasmussen-Torvik LJ, Roden DM, Ritchie MD. Genetic variations among 82 pharmacogenes: the PGRNseq data from the eMERGE Network. *Clin Pharmacol Ther.* 2016; 100:160–9. [PubMed: 26857349]
23. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin Pharmacokinet.* 2016 [Epub ahead of print, 30 March 2016].
24. Hudak ML. Codeine pharmacogenetics as a proof of concept for pediatric precision medicine. *Pediatrics.* 2016; 138:e20161359. [PubMed: 27335381]
25. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein TE, Leeder JS. Prediction of *CYP2D6* phenotype from genotype across world populations. *Genet Med.* 2016 [Epub ahead of print 7 July 2016].
26. Daly AK. Genome-wide association studies in pharmacogenomics. *Nature Rev Genet.* 2010; 11:241–6. [PubMed: 20300088]